Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.

Autor:	Pereda MA; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Hosahalli Vasanna S; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Desai NJ; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Deng V; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Owusu-Ansah A; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Dallas MH; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Pateva I; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States., Dalal J; Department of Pediatrics, Division of Pediatric Hematology Oncology, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, United States.; School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Nov 29; Vol. 13, pp. 1055473. Date of Electronic Publication: 2022 Nov 29 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.1055473
Abstrakt:	Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Pereda, Hosahalli Vasanna, Desai, Deng, Owusu-Ansah, Dallas, Pateva and Dalal.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu